Minimum information about tolerogenic antigen-presenting cells (mitap): a first step towards reproducibility and standardisation of cellular therapies
Lord, Phillip ; Spiering, Rachel ; Aguillon, Juan C. ; Anderson, Amy E. ; Appel, Silke ; Benitez-Ribas, Daniel ; ten Brinke, Anja ; Broere, Femke ; Cools, Nathalie ; Cuturi, Maria Cristina ... show 10 more
Lord, Phillip
Spiering, Rachel
Aguillon, Juan C.
Anderson, Amy E.
Appel, Silke
Benitez-Ribas, Daniel
ten Brinke, Anja
Broere, Femke
Cools, Nathalie
Cuturi, Maria Cristina
Repository DOI
Publication Date
2016-08-30
Type
Article
Downloads
Citation
Lord, Phillip; Spiering, Rachel; Aguillon, Juan C. Anderson, Amy E.; Appel, Silke; Benitez-Ribas, Daniel; ten Brinke, Anja; Broere, Femke; Cools, Nathalie; Cuturi, Maria Cristina; Diboll, Julie; Geissler, Edward K.; Giannoukakis, Nick; Gregori, Silvia; van Ham, S. Marieke; Lattimer, Staci; Marshall, Lindsay; Harry, Rachel A.; Hutchinson, James A.; Isaacs, John D.; Joosten, Irma; van Kooten, Cees; Lopez Diaz de Cerio, Ascension; Nikolic, Tatjana; Oral, Haluk Barbaros; Sofronic-Milosavljevic, Ljiljana; Ritter, Thomas; Riquelme, Paloma; Thomson, Angus W.; Trucco, Massimo; Vives-Pi, Marta; Martinez-Caceres, Eva M.; Hilkens, Catharien M.U. (2016). Minimum information about tolerogenic antigen-presenting cells (mitap): a first step towards reproducibility and standardisation of cellular therapies. PeerJ 4 ,
Abstract
Cellular therapies, with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. Here we describe an initiative by members of the tolAPC field to generate a minimum information model for tolAPC (MITAP), providing a reporting framework that will make differences and similarities between tolAPC products transparent. In this way, MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application.
Funder
Publisher
PeerJ
Publisher DOI
10.7717/peerj.2300
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland